Janssen has a long-standing, continued commitment to neuroscience. Neuroscience disorders represent a significant unmet need that carries a high societal burden, including a significant loss of productivity and a high cost of care. Our vision in is to reduce the burden, disability and devastation caused by serious neuropsychiatric diseases and pain conditions and restore hope for patients.
Led by Dr. Husseini Manji, the Neuroscience Therapeutic Area is focused on finding breakthrough treatments for Alzheimer's disease, mood disorders, psychosis and pain. Our researchers are taking advantage of emerging science in neurodegenerative and neuroinflammatory disorders, including synaptic plasticity and cellular resilience with an emphasis on developing novel therapeutics for the treatment of cognitive and neurodegenerative dementias. Our goal is to leverage technologies in imaging, genomics, and associated biomarkers to provide early disease diagnostics and patient management programs. Along with a strong commitment to our internal research groups, we are dedicated to partnering with individuals and companies that share our vision and want to work together to build the neuroscience treatments of tomorrow.